What is behind Brain Fog & Focus
Insulin-like growth factor-1 — the dermal-papilla growth factor that drives follicle proliferation and prolongs anagen (the active growth phase). Evidence A — Human trial evidence.
The chemistry of wanting, not of liking. Dopamine sets how much effort a goal feels worth — which is why its loss reads as apathy long before it reads as sadness. More is not better: the same system that drives pursuit drives compulsion. Evidence A — Human trial evidence.
Memory and focus neurotransmitter. Evidence A — Human trial evidence.
The master inflammatory switch — indispensable to defend against threat, corrosive when it never stands down. Evidence B — Preclinical.
The cystine–glutamate exchange that supplies antioxidant building blocks while tuning excitatory neurotransmission. Evidence A — Human trial evidence.
The lipid sheath that insulates nerve fibers, setting the speed and precision of neural signaling. Evidence A — Human trial evidence.
A sensor of cellular stress that ignites inflammation driven by damage rather than by germs. Evidence A — Human trial evidence.
Arousal — the wakeful state that gates cognition rather than being part of it. Deliberately not counted as a seventh cognitive domain: it is not one of the dsm-5 six. And more is not better — the arousal literature describes a spectrum with sleepiness and inattention at one end and hypervigilance, panic and psychosis at the other. Evidence B — Preclinical.
Sustained attention — the capacity to keep focus on one task, shift it deliberately, and filter distraction over time.
Evidence on these pathways
Dopamine → Melatonin. “Through α1B-D4 and β1-D4 receptor heteromers dopamine inhibits adrenergic receptor signaling and blocks the synthesis of melatonin induced by adrenergic receptor ligands.” — Circadian-Related Heteromerization of Adrenergic and Dopamine D4 Receptors Modulates Melatonin Synthesis and Release in the Pineal Gland. PLoS Biology, 2012, volume 10, e1001347. doi:10.1371/journal.pbio.1001347
Dopamine → Mood (Positive Affect). “Boosting dopamine also increased happiness resulting from some rewards.” — Dopaminergic Modulation of Decision Making and Subjective Well-Being. Journal of Neuroscience, 2015, 35(27), 9811-9822. doi:10.1523/JNEUROSCI.0702-15.2015 | PMC4495239
Myelin → Perceptual-Motor Function. “We concluded that new oligodendrocytes contribute to both early and late stages of motor skill learning.” — Rapid production of new oligodendrocytes is required in the earliest stages of motor-skill learning. Nature Neuroscience, 2016, 19(9), 1210-1217. doi:10.1038/nn.4351 | PMID 27455109
NF-κB → CD38 NADase. “Regulation of CD38 expression in HASM cells involves the transcription factor NF-κB, and glucocorticoids inhibit this expression through NF-κB-dependent and -independent mechanisms.” — Regulation of the cd38 promoter in human airway smooth muscle cells by TNF-α and dexamethasone. Respiratory Research, 2008, vol 9, 26. doi:10.1186/1465-9921-9-26
Formulas that act on these pathways
Acts on 6 of these pathways: Dopamine, NF-κB, Cystine–Glutamate Antiporter, Myelin, Alertness / Arousal, Sustained Attention.
Acts on 4 of these pathways: Dopamine, NF-κB, Cystine–Glutamate Antiporter, Myelin.
Acts on 4 of these pathways: Dopamine, NF-κB, Myelin, Sustained Attention.
Acts on 3 of these pathways: Dopamine, NF-κB, Cystine–Glutamate Antiporter.
Acts on 3 of these pathways: Dopamine, NF-κB, Cystine–Glutamate Antiporter.
Acts on 2 of these pathways: NF-κB, Cystine–Glutamate Antiporter.
What this page does not claim
This page names the pathways involved and the published evidence on each. It does not claim that any formula treats, cures or prevents Brain Fog & Focus. A pathway opens here only on graded, published evidence, under a standard fixed before the evidence was gathered, and every figure above carries its grade.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.